ClinicalTrials.gg
Active, not recruitingNCT06952478Updated Oct 27, 2026

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

A Phase 3 interventional study of CT-P44(Daratumumab) and Darzalex Faspro(Daratumumab) in Refractory or Relapsed Multiple Myeloma, sponsored by Celltrion. Active, not recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
13th of 132
473 · median 50
Started
2025
with 3 others
Phase 3
24 of 132
4 open now
Primary completion
2027-03
later than 36 of 62 live
Registered
130th of 132
by date

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 13th largest by enrollment, is one of 4 that started in 2025, is one of 24 in phase 3, reaches primary completion later than 36 of the 62 other live ones, and was the 130th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

03

Conditions studied

  • Refractory or Relapsed Multiple Myeloma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Main Inclusion Criteria]

  • Male or female with 18 years of age or older.
  • Patient must have documented multiple myeloma (MM) according to IMWG criteria
  • Patient must have a documented disease.
  • Patient must have achieved a response (PR or better based on investigator's determination of response by the IMWG criteria) to at least one prior regimen.
  • Patient must have a PD or clinical relapse, as defined by the IMWG criteria on or after their last .

[Main Exclusion Criteria]

  • Patient whose body weight is of >120 kg
  • Patient has received daratumumab or any other drug specifically targeting CD38 previously.
  • Patient's disease shows evidence of refractoriness or intolerance to lenalidomide.
  • Patient is known or suspected of not being able to comply with the study protocol (e.g., psychological disorder) or the patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    CT-P44

    CT-P44 1800mg SC (subcutaneous)

    Biological: CT-P44(Daratumumab)

  • Active comparator
    Darzalex Faspro

    Darzalex Faspro 1800mg SC (subcutaneous)

    Biological: Darzalex Faspro(Daratumumab)

Interventions

  • CT-P44 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 26, whichever occurs first.

  • Darzalex Faspro 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 6, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. PK equivalence of CT-P44 and Darzalex Faspro

    AUCWeek0-1 and AUCWeek8-10 of daratumumab.

    Time frame: Week 0 ~ Week 24

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 18 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Nov 2027 → Mar 2027 and completion Jun 2029 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 1, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Mar 8, 2027was Nov 2027
CompletionEst.
Sep 18, 2028was Jun 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Primary completion
Nov 15, 2027→Mar 8, 2027
Oct 21, 2026
Study completion
Jun 25, 2029→Sep 18, 2028
Oct 21, 2026
Enrollment
486 (estimated)→473 (actual)
Oct 21, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedPatient must have a PD or clinical relapse, as defined by the IMWG criteria on or after their last line of therapy.
  • AddedPatient whose body weight is of >120 kg
Oct 21, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedTherapeutic equivalence of CT-P44 and Darzalex FasproTime frame: Week 0 ~ Week 24
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    Primary completion Nov 15, 2027→Mar 8, 2027
    Study completion Jun 25, 2029→Sep 18, 2028
    Enrollment 486 (estimated)→473 (actual)
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedPatient must have a PD or clinical relapse, as defined by the IMWG criteria on or after their last line of therapy.
    • AddedPatient whose body weight is of >120 kg
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedTherapeutic equivalence of CT-P44 and Darzalex FasproTime frame: Week 0 ~ Week 24
    + 4 other changes: verification date, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06952478
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Aug 12, 2025
Primary completion
Mar 8, 2027 (estimated)
Completion
Sep 18, 2028 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion